Predicting therapy-related myeloid neoplasms-and preventing them?

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address: david_steensma@dfci.harvard.edu.

Comment

David P Steensma. Lancet Oncol. 2017 Jan.

. 2017 Jan;18(1):11-13.

doi: 10.1016/S1470-2045(16)30622-2. Epub 2016 Dec 4.

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address: david_steensma@dfci.harvard.edu.

No abstract available

Comment on

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Takahashi K, et al. Lancet Oncol. 2017 Jan;18(1):100-111. doi: 10.1016/S1470-2045(16)30626-X. Epub 2016 Dec 3. Lancet Oncol. 2017. PMID: 27923552 Free PMC article.
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.
Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Gillis NK, et al. Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4. Lancet Oncol. 2017. PMID: 27927582 Free PMC article.